NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 7, 2003, Pages 851-859

  Nakagami, Hironori ^a   Takemoto, Masao ^a   Liao, James K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II; Antioxidants; Cardiomyocyte; G proteins; Hypertrophy; NADPH oxidase; Reactive oxygen species

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLCYSTEINE; ALPHA ACTININ; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; CATALASE; DESMIN; LOSARTAN; MACROGOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

AMINO ACID TRANSPORT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; HEART VENTRICLE HYPERTROPHY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; REDUCTION;

EID: 0037785315     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00145-7     Document Type: Article

References (29)

1. Frohlich E.D. Cardiac hypertrophy in hypertension. New Engl J M. 317:1987;831-833.
2. McLenachan J.M., Henderson E., Morris K.I., Dargie H.J. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. New Engl J M. 317:1987;787-792.
3. Vasan R.S., Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Int M. 156:1996;1789-1796.
4. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 59:2001;646-654.
5. +-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem. 274:1999;19323-19328.
6. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 98:1998;794-799.
7. Tanaka K., Honda M., Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol. 37:2001;676-685.
8. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 108:2001;1429-1437.
9. Abid M.R., Tsai J.C., Spokes K.C., Deshpande S.S., Irani K., Aird W.C. Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism. FASEB J. 15:2001;2548-2550.
10. Lynn S., Gurr J.R., Lai H.T., Jan K.Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res. 86:2000;514-519.
11. Matsubara T., Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J Immunol. 137:1986;3295-3298.
12. Ohara Y., Peterson T.E., Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
13. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem J. 318:1996;379-382.
14. Chien K.R., Knowlton K.U., Zhu H., Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 5:1991;3037-3046.
15. Kim S., Ohta K., Hamaguchi A., Yukimura T., Miura K., Iwao H. Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension. 25:1995;1252-1259.
16. Nakamura R., Egashira K., Machida Y., Hayashidani S., Takeya M., Utsumi H., et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 106:2002;362-367.
17. Date M.O., Morita T., Yamashita N., Nishida K., Yamaguchi O., Higuchi Y., et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol. 39:2002;907-912.
18. Katoh M., Egashira K., Usui M., Ichiki T., Tomita H., Shimokawa H., et al. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 83:1998;743-751.
19. Suzuki J., Matsubara H., Urakami M., Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 73:1993;439-447.
20. Harada K., Komuro I., Shiojima I., Hayashi D., Kudoh S., Mizuno T., et al. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 97:1998;1952-1959.
21. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
22. 2 in angiotensin II-induced vascular hypertrophy. Hypertension. 32:1998;488-495.
23. Bendall J.K., Cave A.C., Heymes C., Gall N., Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II- induced cardiac hypertrophy in mice. Circulation. 105:2002;293-296.
24. Ruzicka M., Yuan B., Harmsen E., Leenen F.H. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 87:1993;921-930.
25. Mankad S., d'Amato T.A., Reichek N., McGregor W.E., Lin J., Singh D., et al. Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation. 103:2001;2845-2850.
26. Dorn G.W. II, Brown J.H. Gq signaling in cardiac adaptation and maladaptation. Trend Cardiovasc M. 9:1999;26-34.
27. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F.J., Neer E.J. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci USA. 95:1998;13893-13898.
28. Sah V.P., Hoshijima M., Chien K.R., Brown J.H. Rho is required for Galphaq and alpha1-adrenergic receptor signaling in cardiomyocytes. Dissociation of Ras and Rho pathways. J Biol Chem. 271:1996;31185-31190.
29. Thorburn A., Thorburn J., Chen S.Y., Powers S., Shubeita H.E., Feramisco J.R., et al. HRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem. 268:1993;2244-2249.